Role of genetic polymorphisms and ovarian cancer susceptibility

Peter A. Fasching, Simon Gayther, Leigh Pearce, Joellen M. Schildkraut, Ellen L Goode, Falk Thiel, Georgia Chenevix-Trench, Jenny Chang-Claude, Shan Wang-Gohrke, Susan Ramus, Paul Pharoah, Andrew Berchuck

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

The value of identifying women with an inherited predisposition to epithelial ovarian cancer has become readily apparent with the identification of the BRCA1, and BRCA2 genes. Women who inherit a deleterious mutation in either of these genes have a very high lifetime risk of ovarian cancer (10-60%) and to some extent, increased risks of fallopian tube and peritoneal cancer. These highly lethal cancers are almost completely prevented by prophylactic salpingoophorectomy. BRCA1/2 mutation testing has become the accepted standard of care in families with a strong history of breast and/or ovarian cancer. This approach has the potential to reduce ovarian cancer mortality by about 10%. Although the ability to perform genetic testing for BRCA1 and 2 represents a significant clinical advance, the frequency of mutations in these high penetrance ovarian cancer susceptibility genes is low in most populations. There is evidence to suggest that ovarian cancer susceptibility might be affected by common low penetrance genetic polymorphisms like it was shown for several common disorders like diabetes or breast cancer. Although such polymorphisms would increase risk to a lesser degree, they could contribute to the development of a greater proportion of ovarian cancers by virtue of their higher frequencies in the population. It has been shown that the most powerful approach to studying low penetrance genes is an association study rather than a linkage study design. This review describes the efforts that have been made in this field by individual case-control studies and through multi-center collaborations as part of international consortia such as the Ovarian Cancer Association Consortium (OCAC).

Original languageEnglish (US)
Pages (from-to)171-181
Number of pages11
JournalMolecular Oncology
Volume3
Issue number2
DOIs
StatePublished - Apr 2009

Fingerprint

Genetic Polymorphisms
Ovarian Neoplasms
Penetrance
Fallopian Tube Neoplasms
BRCA2 Gene
Breast Neoplasms
BRCA1 Gene
Mutation
Aptitude
Neoplasm Genes
Genetic Testing
Mutation Rate
Standard of Care
Population
Genes
Case-Control Studies
Mortality
Neoplasms

Keywords

  • Early detection
  • Genetic
  • Ovarian cancer
  • Polymorphism
  • Risk
  • SNP

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Medicine

Cite this

Fasching, P. A., Gayther, S., Pearce, L., Schildkraut, J. M., Goode, E. L., Thiel, F., ... Berchuck, A. (2009). Role of genetic polymorphisms and ovarian cancer susceptibility. Molecular Oncology, 3(2), 171-181. https://doi.org/10.1016/j.molonc.2009.01.008

Role of genetic polymorphisms and ovarian cancer susceptibility. / Fasching, Peter A.; Gayther, Simon; Pearce, Leigh; Schildkraut, Joellen M.; Goode, Ellen L; Thiel, Falk; Chenevix-Trench, Georgia; Chang-Claude, Jenny; Wang-Gohrke, Shan; Ramus, Susan; Pharoah, Paul; Berchuck, Andrew.

In: Molecular Oncology, Vol. 3, No. 2, 04.2009, p. 171-181.

Research output: Contribution to journalArticle

Fasching, PA, Gayther, S, Pearce, L, Schildkraut, JM, Goode, EL, Thiel, F, Chenevix-Trench, G, Chang-Claude, J, Wang-Gohrke, S, Ramus, S, Pharoah, P & Berchuck, A 2009, 'Role of genetic polymorphisms and ovarian cancer susceptibility', Molecular Oncology, vol. 3, no. 2, pp. 171-181. https://doi.org/10.1016/j.molonc.2009.01.008
Fasching PA, Gayther S, Pearce L, Schildkraut JM, Goode EL, Thiel F et al. Role of genetic polymorphisms and ovarian cancer susceptibility. Molecular Oncology. 2009 Apr;3(2):171-181. https://doi.org/10.1016/j.molonc.2009.01.008
Fasching, Peter A. ; Gayther, Simon ; Pearce, Leigh ; Schildkraut, Joellen M. ; Goode, Ellen L ; Thiel, Falk ; Chenevix-Trench, Georgia ; Chang-Claude, Jenny ; Wang-Gohrke, Shan ; Ramus, Susan ; Pharoah, Paul ; Berchuck, Andrew. / Role of genetic polymorphisms and ovarian cancer susceptibility. In: Molecular Oncology. 2009 ; Vol. 3, No. 2. pp. 171-181.
@article{a9d28254af2a49af9cc761ccc831aef2,
title = "Role of genetic polymorphisms and ovarian cancer susceptibility",
abstract = "The value of identifying women with an inherited predisposition to epithelial ovarian cancer has become readily apparent with the identification of the BRCA1, and BRCA2 genes. Women who inherit a deleterious mutation in either of these genes have a very high lifetime risk of ovarian cancer (10-60{\%}) and to some extent, increased risks of fallopian tube and peritoneal cancer. These highly lethal cancers are almost completely prevented by prophylactic salpingoophorectomy. BRCA1/2 mutation testing has become the accepted standard of care in families with a strong history of breast and/or ovarian cancer. This approach has the potential to reduce ovarian cancer mortality by about 10{\%}. Although the ability to perform genetic testing for BRCA1 and 2 represents a significant clinical advance, the frequency of mutations in these high penetrance ovarian cancer susceptibility genes is low in most populations. There is evidence to suggest that ovarian cancer susceptibility might be affected by common low penetrance genetic polymorphisms like it was shown for several common disorders like diabetes or breast cancer. Although such polymorphisms would increase risk to a lesser degree, they could contribute to the development of a greater proportion of ovarian cancers by virtue of their higher frequencies in the population. It has been shown that the most powerful approach to studying low penetrance genes is an association study rather than a linkage study design. This review describes the efforts that have been made in this field by individual case-control studies and through multi-center collaborations as part of international consortia such as the Ovarian Cancer Association Consortium (OCAC).",
keywords = "Early detection, Genetic, Ovarian cancer, Polymorphism, Risk, SNP",
author = "Fasching, {Peter A.} and Simon Gayther and Leigh Pearce and Schildkraut, {Joellen M.} and Goode, {Ellen L} and Falk Thiel and Georgia Chenevix-Trench and Jenny Chang-Claude and Shan Wang-Gohrke and Susan Ramus and Paul Pharoah and Andrew Berchuck",
year = "2009",
month = "4",
doi = "10.1016/j.molonc.2009.01.008",
language = "English (US)",
volume = "3",
pages = "171--181",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Role of genetic polymorphisms and ovarian cancer susceptibility

AU - Fasching, Peter A.

AU - Gayther, Simon

AU - Pearce, Leigh

AU - Schildkraut, Joellen M.

AU - Goode, Ellen L

AU - Thiel, Falk

AU - Chenevix-Trench, Georgia

AU - Chang-Claude, Jenny

AU - Wang-Gohrke, Shan

AU - Ramus, Susan

AU - Pharoah, Paul

AU - Berchuck, Andrew

PY - 2009/4

Y1 - 2009/4

N2 - The value of identifying women with an inherited predisposition to epithelial ovarian cancer has become readily apparent with the identification of the BRCA1, and BRCA2 genes. Women who inherit a deleterious mutation in either of these genes have a very high lifetime risk of ovarian cancer (10-60%) and to some extent, increased risks of fallopian tube and peritoneal cancer. These highly lethal cancers are almost completely prevented by prophylactic salpingoophorectomy. BRCA1/2 mutation testing has become the accepted standard of care in families with a strong history of breast and/or ovarian cancer. This approach has the potential to reduce ovarian cancer mortality by about 10%. Although the ability to perform genetic testing for BRCA1 and 2 represents a significant clinical advance, the frequency of mutations in these high penetrance ovarian cancer susceptibility genes is low in most populations. There is evidence to suggest that ovarian cancer susceptibility might be affected by common low penetrance genetic polymorphisms like it was shown for several common disorders like diabetes or breast cancer. Although such polymorphisms would increase risk to a lesser degree, they could contribute to the development of a greater proportion of ovarian cancers by virtue of their higher frequencies in the population. It has been shown that the most powerful approach to studying low penetrance genes is an association study rather than a linkage study design. This review describes the efforts that have been made in this field by individual case-control studies and through multi-center collaborations as part of international consortia such as the Ovarian Cancer Association Consortium (OCAC).

AB - The value of identifying women with an inherited predisposition to epithelial ovarian cancer has become readily apparent with the identification of the BRCA1, and BRCA2 genes. Women who inherit a deleterious mutation in either of these genes have a very high lifetime risk of ovarian cancer (10-60%) and to some extent, increased risks of fallopian tube and peritoneal cancer. These highly lethal cancers are almost completely prevented by prophylactic salpingoophorectomy. BRCA1/2 mutation testing has become the accepted standard of care in families with a strong history of breast and/or ovarian cancer. This approach has the potential to reduce ovarian cancer mortality by about 10%. Although the ability to perform genetic testing for BRCA1 and 2 represents a significant clinical advance, the frequency of mutations in these high penetrance ovarian cancer susceptibility genes is low in most populations. There is evidence to suggest that ovarian cancer susceptibility might be affected by common low penetrance genetic polymorphisms like it was shown for several common disorders like diabetes or breast cancer. Although such polymorphisms would increase risk to a lesser degree, they could contribute to the development of a greater proportion of ovarian cancers by virtue of their higher frequencies in the population. It has been shown that the most powerful approach to studying low penetrance genes is an association study rather than a linkage study design. This review describes the efforts that have been made in this field by individual case-control studies and through multi-center collaborations as part of international consortia such as the Ovarian Cancer Association Consortium (OCAC).

KW - Early detection

KW - Genetic

KW - Ovarian cancer

KW - Polymorphism

KW - Risk

KW - SNP

UR - http://www.scopus.com/inward/record.url?scp=63549147327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63549147327&partnerID=8YFLogxK

U2 - 10.1016/j.molonc.2009.01.008

DO - 10.1016/j.molonc.2009.01.008

M3 - Article

C2 - 19383379

AN - SCOPUS:63549147327

VL - 3

SP - 171

EP - 181

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 2

ER -